Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D…
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced that it…
Read More...
Read More...
